About Encoded Therapeutics
Encoded Therapeutics is a clinical-stage genetic medicines company developing one-time, disease-modifying gene therapies for severe neurological disorders. Its vector engineering platform enables highly selective, potent, and durable gene modulation targeting specific cell types. The lead program, ETX101, is designed to treat SCN1A+ Dravet syndrome and is currently in Phase 1/2 clinical trials.
Company details
Funding
Total raised
$299M
Last stage
Series D
Investors
Founders
Kartik Ramamoorthi
Co-founder and CEO of Encoded Therapeutics. Holds a Ph.D. in Molecular & Cellular Neuroscience from MIT (2014) and was previously on the founding team at Voyager Therapeutics.
LinkedIn
Stephanie Tagliatela
Co-founder and CSO of Encoded Therapeutics. Conducted doctoral research in Molecular and Cellular Neuroscience at MIT; holds a B.A. in Biological Sciences from Mount Holyoke College.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.